Abstract
2022 Background: AGN 195183 is a novel retinoid that trans-activates retinoic acid receptor-α (RAR-α). In preclinical models, AGN 195183 caused less skin toxicity compared to RAR interactive agents lacking RAR-α specificity and demonstrated anti-tumor activity in breast cancer and leukemia models. We initiated a clinical trial of AGN 195183 in advanced solid tumor patients (pts) in order to establish toxicity and pharmacokinetic profiles and to establish the maximum tolerated dose (MTD). Methods: Fifteen pts with advanced solid tumors meeting standard phase I entry criteria were enrolled on study; mean age was 60 years (range 45–79). Pts took AGN 195183 (5 and 50 mg soft gelatin capsules) by mouth with or without food on a continuous daily dosing schedule. Pharmacokinetic (PK) blood samples were collected on the days 1 and 14 prior to dosing and at 0.5, 1, 1.5, 2, 3, 5, 8, and 24 hours post-dose and prior to and 1 hour post-dose on days 7, 21, and 28. Results: Five pts were treated at the starting dose level of 60 mg/m2/d; 2 pts had a dose limiting toxicity (DLT) including grade 3 elevation of alk phos (pt also had progressing liver metastases) and gr 3 mucositis. Drug was de-escalated to 30 mg/m2/d; 2 of 4 pts treated had gr 3 elevation of alkaline phosphatase. Further de-escalation to 15 mg/m2/d has been well tolerated by 6 pts for 17 treatment cycles, with no grade 3 or higher toxicity noted. Preliminary PK studies for 60 mg/m2/d dose level show the drug is absorbed rapidly and reached peak concentration at about one hour post-dose. The average terminal elimination half-life was 4.17 hours. Cmax ranged from 684 to 7660 ng/mL and AUC from 4140 to 31246 95183 ng-hr/mL in 3 pts. Conclusion: AGN 195183 is a novel retinoid that trans-activates retinoic acid receptor-α (RAR-α); it has been well tolerated on an oral daily dosing schedule of 15 mg/m2/d, which is the MTD and recommended Phase II dose. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Allergan Allergan Allergan
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
